Core 1: Biospecimen and Biomarker Core

生物标本和生物标志物核心提供了生物标本科学的领导和专业知识， 本P01研究胶质瘤分子亚型代谢特征所需的分子分析 改善患者管理。高质量、注释良好的生物标本， 肿瘤组织的分析对于检验与科学项目相关的假设是必不可少的。的 核心将从手术中获取、注释、分发、跟踪和分析脑肿瘤患者的生物标本。 房间这将包括图像引导和多个空间映射样本的采集和分析 来自新诊断和复发的胶质瘤患者。此外，核心将提供组织病理学和 人胶质瘤异种移植物的分子分析。本核心的所有方面均按照 2016年国家癌症研究所生物储存指南最佳实践中提出的指导原则。的 生物标本和生物标志物核心的具体目标如下： 1.获取和保存高质量的生物标本，包括图像引导和空间映射组织 样本，从手术室，以满足组织的增量要求的科学项目。 2.进行项目要求的临床相关分子分析。 3.提供神经病理学专业知识，以解释处理后的组织切片和提取 适当的定量和半定量参数。 4.维护与大脑相关的相关分子参数的组织库存和数据库 肿瘤中心数据库，整合了影像学、临床、分子和病理学数据。 5.对核心活动进行一致的监督，以确保严格遵守 关于知情同意和患者保密的法规，以及 生物标本和从生物标本中获得的信息。

The Biospecimen and Biomarker Core provides the leadership and expertise in biospecimen sciences and molecular analyses needed in this P01 to investigate the metabolic signatures of molecular subtypes of glioma to improve patient management. High-quality, well-annotated biospecimens and rigorous and standardized analysis of tumor tissue are essential for testing the hypotheses associated with the scientific Projects. The Core will acquire, annotate, distribute, track, and analyze brain tumor patient biospecimens from the operating room. This will include the acquisition and analysis of image-guided and multiple spatially mapped samples from patients with newly-diagnosed and recurrent glioma. In addition, the Core will provide histopathologic and molecular analysis of human glioma xenografts. All aspects of this Core are performed in accordance with the guiding principles set forth in the 2016 National Cancer Institute Best Practice for Biorepository Guidelines. The specific aims of the Biospecimen and Biomarker Core are as follows: 1. To acquire and preserve high-quality biospecimens, including image-guided and spatially mapped tissue samples, from the operating room to meet the tissue accrual requirements for the scientific projects. 2. To perform the clinically relevant molecular analyses required by the Projects. 3. To provide the neuropathologic expertise for interpretation of the processed tissue sections and extraction of appropriate quantitative and semi-quantitative parameters. 4. To maintain a tissue inventory and database of associated molecular parameters that is linked to the Brain Tumor Center Database, integrating imaging, clinical, molecular, and pathology data. 5. To provide consistent oversight of the Core activities that will ensure the stringent compliance with regulations governing informed consent and patient confidentiality, as well as management of the biospecimens and the information derived from the biospecimens.